Welcome to the Division of Chemical & Systems Biology

Home > Research Groups > Barth Group > Publications

Barth Publications

  • 2021

    1. Madheswaran S., Mungra N., Nsole Biteghe F.A., De la Croix Ndong J., Arowolo A.T., Adeola H.A., Ramamurthy D., Naran K., Khumalo N.P., Barth S. – Antibody based targeted interventions for the diagnosis and treatment of skin cancers. Anti-Cancer Agents in Medicinal Chemistry 21(2): 162-186 (2021), doi: 10.2174/1871520620666200728123006.

    2. Seidel M., Addai-Mensah O., Spiegel H., Chiegoua Dipah G.N., Schmitz S., Breuer G., Frempong M., Reimann A., Klockenbring T., Fischer R.*, Barth S.*, Fendel R.* – Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity. Malaria Journal 20(1): 37 (2021), doi: 10.1186/s12936-020-03548-3.

  • 2020

    1. Nsole Biteghe F.A.*, Mungra N.*, Toung Chalomie N.E., De La Croix Ndong J., Engohang-Ndong J., Vignaux G., Padayachee E., Naran K.*, Barth S.* - Advances in epidermal growth factor receptor specific immunotherapy – lessons to be learned from armed antibodies. Oncotarget 11(38): 3531-3557 (2020), doi: 10.18632/oncotarget.27730.

    2. Nsole Biteghe F.A.*, Toung Chalomie N.E.*, Mungra N., Vignaux G., Gao N., Vergeade A., Okem A., Naran K., De La Croix Ndong J.*, Barth S.* - Antibody-based immunotherapy: alternative approaches for the treatment of metastatic melanoma. Biomedicines 8: 327 (2020), doi:10.3390/biomedicines8090327.

    3. Nsole Biteghe F.A., Ekome Toung C.N., Delacroix Ndong J., Davids L.M., Padayachee E., Barth S. - Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazine. Journal of Photochemistry and Photobiology B: Biology 211. 111982 (2020), doi: 10.1016/j.photobiol.2020.111982.

    4. Ramamurthy D., Nundalall T., Cingo S., Mungra N., Karan M., Naran K.*, Barth S.* - Recent advances in immunotherapies against infectious diseases. Immunotherapy Advances 1(1): 1-16 (2020), doi: 10.1093/immadv/Itaa007.

    5. Thurner L., Hartmann S., Bewarder M., Fadle N., Regitz E., Körbel C., Schormann C., Quiroga N., Kemele M., Klapper W., Rosenwald A., Trümper L., Bohle R.M., Nimmesgern A., Laschke M.W., Barth S., Kubuschock B., Kaddu-Mulindwa D., Hansmann M.L., Pöschel V., Held G., Murawski N., Stilgenbauer S., Neumann F., Preuss K.D., Pfreundschuh M. – Identification of an atypically posttranslational modified autoantigen as the target of B-cell receptors from ABC-type diffuse large B-cell lymphoma. Haematologica: early view (2020), doi: 10.3324/haematol.2019.241653.

    6. Woitok M., Grieger E., Akinrinmade O.A., Bethke S., Pham A.T., Stein C., Fendel R., Fischer R., Barth S., Niesen J. – Using the SNAP-tag technology to easily measure and demonstrate apoptotic changes in cancer and blood cells with different dyes. PLoS ONE 15(12): 0243286, doi: 10.1371/journal.pone.0243286.

    7. Xu Y., Zhang X., Wang N., Pei X., Guo Y., Wang J., Barth S., Yu F., Lee S.J., He H., Yang V.C. – Cell-penetrating peptide enhanced insulin buccal absorption. International Journal of Pharmaceutics 584: 119469 (2020), doi: 10.1016/j.ijpharm.2020.119469.

  • 2019

    1. Hussain A.F., Kampmeier F., Meinhold-Heerlein I., Barth S. – One step site-specific antibody fragment conjugation using SNAP tag technology. Nature Protocols 14: 3101-3125 (2019), doi: 10.1038/s41596-019-0214-y.

    2. Mungra N., Jordaan S., Hlongwane P., Naran K., Chetty S., Barth S. – Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells. Oncotarget 10: 897-915 (2019), doi: 10.18632/oncotarget.26618.

    3. Nachreiner I., Hussain A.F., Wüllner U., Machuy N., Meyer T.F., Fischer R., Gattenlöhner S., Meinhold-Heerlein I., Barth S.*, Tur M.K.* – Elimination of Her3-expressing breast cancer cells using aptamer-iRNA chimeras. Exp Ther Med 18(4): 2401-2412 (2019), doi: 10.3892/etm.2019.7753.

    4. Padayachee E.R., Adeola H.A., van Wyk J.C., Nsole Biteghe F.A., Chetty S., Khumalo N.P., Barth S. – Applications of SNAP-tag technology in skin cancer therapy. Health Science Reports: e103 (2019), doi: 10.1002/hsr2.103.

  • 2018

    1. Chouman K., Korioth-Schmitz B., Sack M., Schmitz J.E., Pham A.T., Fischer R., Barth S., Klockenbring T., Fendel R. – Characterization of new anti-IL-6 antibodies revealed high potency candidates for intracellular cytokine detection and specific targeting of IL-6 receptor binding sites. Eur Cytokine Netw 29(2): 59-72 (2018), doi: 10.1684/ecn.2018.0409.

    2. Dhandapani R., Arokiaraj C.M., Taberner F., Raja S., Portulano C., Franciosa F., Maffei M., Hussain A.F., de Castro Reis F., Reymond L., Perlas E., Barth S., Johnsson K., Lechner S.G., Heppenstall P.A. – Control of mechanical pain hypersensitivity in mice through ligand-targeted photoablation of TrkB positive sensory neurons. Nature Commun 9(1): 1640 (2018), doi: 10.1038/s41467-018-04049-3.

    3. Hlongwane P., Mungra N., Madheswaran S., Akinrinmade O.A., Chetty S.*, Barth S.* – Human granzyme B based targeted cytolytic fusion proteins. Biomedicines 6(2): 72 (2018), doi: 10.3390/biomedicines6020072.

    4. Jordaan S.*, Akinrinmade O.A.*, Nachreiner T., Cremer C., Islam M., Chetty S.*, Barth S.* – Updates in the development of immunoRNases for the selective killing of tumor cells. Biomedicines 6(1): 28 (2018), doi: 10.3390/biomedicines6010028.

    5. Naran K., Nundalall T., Chetty S., Barth S. – Principles of immunotherapy: implication for treatment strategies in cancer and infectious diseases. Front Microbiol 9: 3158 (2018), doi: 10.3389/fmicb.2018.03158.

    6. Wollschlaeger C., Meinhold-Heerlein I., Cong X., Bräutigam K., Di Fiore S., Zeppernick F., Klockenbring T., Stickeler E., Barth S.*, Hussain A.F.* – Simultaneous and independent dual site-specific self-labeling of recombinant proteins. Bioconjugate Chemistry 29(11): 3586-3594 (2018), doi: 10.1021/acs.bioconchem.8b00545.

  • 2017

    1. Akinrinmade O.A.*, Jordaan S.*, Hristodorov D., Mladenov R., Mungra N., Chetty S.*, Barth S.* - Human MAP tau based targeted cytolytic fusion proteins. Biomedicines 5(3): E36 (2017), doi: 10.3390/biomedicines5030036.

    2. Akinrinmade O.A., Chetty S., Daramola A.K., Islam M.U., Thepen T., Barth S. – CD64: an attractive immunotherapeutic target for M1-type macrophage mediated chronic inflammatory diseases. Biomedicines 5(3): E56 (2017), doi: 10.3390/biomedicines5030056.

    3. Bauerschlag D., Meinhold-Heerlein I., Maass N., Bleilevens A., Bräutigam K., Al Rawashdeh W., Di Fiore S., Haugg A.M., Gremse F., Steitz J., Fischer R., Stickeler E., Barth S., Hussain A.F. – Detection and specific elimination of EGFR+ ovarian cancer cells using a near infrared photoimmunotheranostics approach. Pharm Res 34(4): 696-703 (2017), doi: 10.1007/s11095-017-2096-4.

    4. Bochicchio A., Jordaan S., Losasso V., Chetty S., Casanovas Perera R., Ippoliti E., Barth S.*, Carloni P.* – Designing the sniper: improving targeted human cytolytic fusion proteins for anti-cancer therapy via molecular simulation. Biomedicines 5(1): E9 (2017), doi: 10.3390/biomedicines5010009.

    5. Choudhary S., Barth S.*, Verma R.* – SNAP-tag technology: a promising tool for ex vivo immunophenotyping. Mol Diagn Ther 21(3): 315-326 (2017), PMID: 28164252, doi: 10.1007/s40291-017-0263-2.

    6. Gresch G., Schenke L., Mlandenov R., Zwirner S., Cremer C., Niesen J., Grieger E., Brümmendorf T., Jost E., Fischer R., Stockmeyer B., Barth S., Nachreiner T., Stein C. – Elimination of different leukaemia subtypes using novel CD89-specific human cytolyic fusion proteins. Brit J Haematol 183(2): 313-317 (2017), doi: 10.1111/bjh.14971.

    7. Grieger E., Gresch G., Niesen J., Woitok M., Barth S., Fischer R., Fendel R., Stein C. – Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA’ and the bispecific scFv [13xds16]. J Cancer Res Clin Oncol 143(11): 2159-2170 (2017), doi: 10.1007/s00432-017-2468-5.

    8. Jordaan S., Chetty S., Mungra N., Koopmans I., van Bommel P.E., Helfrich W., Barth S. – CSPG4: a target for selective delivery of human cytolytic fusion proteins and TRAIL. Biomedicines 5(3): E37 (2017), doi: 10.3390/biomedicines5030037.

    9. Kessler C., Pardo A., Gattenlöhner S., Fischer R., Kolberg K., Barth S. – Novel PSCA-targeting scFv fusion proteins for diagnosis and immunotherapy of prostate cancer. J Cancer Res Clin Oncol 143(10): 2025-2038 (2017), doi: 10.1007/s00432-017-2472-9

    10. Klose D., Woitok M., Niesen J., Beerli R.R., Grawunder U., Fischer R., Barth S., Fendel R., Nachreiner T. – Generation of an artificial B cell line test system using Transpo-mAb technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins. PLoS One 12(7): e0180305 (2017), doi: 10.1371/journal.pone.o1800305.

    11. Padayachee E.R., Biteghe F.A.N., Malindi Z., Bauerschlag D.*, Barth S.* - Human antibody fusion proteins/antibody drug conjugates in breast and ovarian cancer. Transfus Med Hemother 44(5): 303-310 (2017), doi: 10.1159/000479979

    12. Tur M.K., Daramola A.K., Gattenlöhner S., Herling M., Chetty S.*, Barth S.* - Restoration of DAP kinase tumor suppressor function: a therapeutic strategy to selectively induce apoptosis in cancer cells using immunokinase fusion proteins. Biomedicines 5(4): E59 (2017), doi: 10.3390/biomedicines5040059

    13. Woitok M., Klose D., DiFiore S., Richter W., Stein C., Gresch G., Grieger E., Barth S., Fischer R., Kolberg K., Niesen J. – Comparison of mouse and human scFv-SNAP-auristatin F drug conjugates with potent activity against EGFR overexpressing solid tumor cells. OncoTargets Ther 10: 3313-3327 (2017), doi: 10.2147/OTT.S140492.

  • 2016

    1. Addai-Mensah O., Seidel M., Amidu N., Maskus D.J., Kapelski S., Breuer C., Franken C., Owusu-Dabo E., Frempong M., Rakotozandrinddrainy R., Schinkel H., Reimann A., Klockenbring T., Barth S., Fischer R., Fendel R. – Acquired immune responses to three malaria vaccine candidates and their relationship to invasion inhibition in two populations naturally exposed to malaria. Malaria J. 15(1): 65 (2016). PMID: 26850066, doi: 10.1186/s12936-016-1112-1.

    2. Amoury M., Bauerschlag D., Zeppernick F., von Felbert V., Berges N., Di Fiore S., Mintert I., Bleilevens A., Maass N., Bräutigam K., Meinhold-Heerlein I., Stickeler E., Barth S.*, Fischer R.*, Hussain A.F.* – Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand. Oncotarget: accepted (2016), PMID: 27448975, doi: 10.18632/oncotarget.10705.

    3. Amoury M., Kolberg K., Pham A.T., Hristodorov D., Mladenov R., Di Fiore S., Helfrich W., Kiessling F., Fischer R., Pardo A., Thepen T., Nachreiner T., Barth S. - Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple-negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. Cancer Letters 372(2): 201-9 (2016), PMID: 26806809, doi: 10.1016/j.canlet.2016.01.027.

    4. Amoury M., Mladenov R., Nachreiner T., Pham A.T., Hristodorov D., Di Fiore S., Helfrich W., Pardo A., Fey G., Thepen T., Kiessling F., Kolberg K., Barth S. - A novel approach for targeted elimination of CSPG4-positive triple negative breast cancer using a MAP-tau based fusion protein. Int J Cancer 139(4): 916-24 (2016). PMID: 27037627, doi: 10.1002/ijc.30119.

    5. Bialon M., Grezella C., Friesen L., Sieben T., Pham A.T., Fischer R., Barth S., Püttmann C., Stein C. - A monoclonal antibody that discriminates between SNAP- and CLIP-tagged proteins. Monoclon Antib Immunodiagn Immunother 35(3): 141-7 (2016). PMID: 27187007, doi: 10.1089/mab.2016.0002.

    6. Choudhary S., Pardo S., Rosinke R., Batra J.K. , Barth S.*, Verma R.S.* - Targeting c-kit receptor in neuroblastomas and colorectal cancers using Stem Cell Factor (SCF) l-based recombinant bacterial toxins. Appl Microbiol Biotechnol 100(1): 263-77 (2016), PMID: 26428235, doi: 10.1007/s00253-015-6978-2.

    7. Cong C., Cremer C., Nachreiner T., Barth S.*, Carloni P.* – Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations. Protein Science 25(8): 1451-60 (2016). PMID: 27110669, doi: 10.1002/pro.2941.

    8. Damm T., Spiegel H., Barth S., Fischer R., Naehring J. - Development of a competitive cystatin-specific bioassay for repetitive measurements. PLOS ONE 11(1): e0147177 (2016), PMID: 26799562, doi: 10.1371/journal.pone.0147177.

    9. Hristodorov D., Mladenov R., Huhn M., Fischer R., Barth S.*, Thepen T.* – Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64+ M1 macrophages. Immunol Cell Biol 94(5): 470-8 (2016), PMID: 26743033, doi: 10.1038/icb.2016.4.

    10. Klose D., Saunders U., Barth S., Fischer R., Jacobi A.M., Nachreiner T. - Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment (TTC) model antigen. BMC Biotechnology 16: 18 (2016), doi: 10.1186/s12896-016-0249-x.

    11. Lilienthal N., Lohmann G., Crispatzu G., Vasyutina E., Zittrich S., Mayer P., Herling C.D., Tur M.K., Hallek M., Pfitzer G., Barth S., Herling M. – A novel CD22 scFv immunoligand restores lost activity of death-associated protein kinase (DAPK) in neoplastic B cells and mediates specific cytotoxicity. Molecular Cancer Therapeutics 15(5): 971-84 (2016), PMID 26826117; doi: 10.1158/1535-7163.MCT-15-0685.

    12. Mladenov R., Hristodorov D., Cremer C., Gresch G., Grieger E., Schenke L., Klose D., Amoury M., Woitok M., Jost E., Brümmendorf F.H., Fendel R., Fischer R., Stein C., Thepen T.*, Barth S.* – CD64-directed microtubule associated protein tau kills leukaemic blasts ex vivo. Oncotarget: accepted (2016)

    13. Niesen J., Hehmann-Titt G., Woitok M., Fendel R., Barth S., Fischer R., Stein C. – A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor. Cancer Letters 374: 229-240 (2016), PMID: 26912070; doi: 10.1016/j.canlet.2016.02.020.

    14. Niesen J., Sack M., Seidel M., Fendel R., Barth S., Fischer R., Stein C. – SNAP-tag technology: a useful tool to determine affinity constants and other functional parameters of novel antibody fragments. Bioconjug Chem 27(8): 1931-41 (2016). PMID: 27391930; doi: 10.1021/acs.bioconjchem.6b00315.

    15. Von Felbert V., Bauerschlag D., Maass N., Bräutigam K., Meinhold-Heerlein I., Woitok M., Barth S.*, Hussain A.F.* - A specific photoimmuno-theranostics agent to detect and eliminate skin cancer cells expressing EGFR. Journal of Cancer Research and Clinical Oncology 142(5): 1003-11 (2016), PMID 26847542, doi: 10.1007/s00432-016-2122-7.

    16. Woitok M., Klose D., Niesen J., Richter W., Abbas M., Hussain A., Stein C., Bialon M., Püttmann C., Fischer R., Barth S.*, Kolberg K.* – The efficient elimination of solid tumor cells by EGFR- and Her2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F. Cancer Letters 381(2): 323-30 (2016). PMID: 27502168, doi: 10.1016/j.canlet.2016.08.003.

  • 2015

    1. Brehm H., Hristodorov D., Pardo A., Mladenov R., Niesen J., Fischer R., Tur M.K., Barth S. - Targeted killing of rhabdomyosarcoma by a MAP-based human cytolytic fusion proteins. Cancer Lett 365(2): 149-55 (2015), PMID: 25888452, doi: 10.1016/j.canlet.2015.04.004

    2. Cremer C., Braun H., Mladenov R., Hein L., Cong X., Jost E., Brümmendorf T.H., Fischer R., Carloni P., Barth S.*, Nachreiner T.* - Novel angiogenin mutants with increased cytotoxicity show enhanced depletion of proinflammatory macrophages and leukemia cells ex vivo. Cancer Immunol Immunother 64(12): 1575-86 (2015), PMID: 26472728, doi: 10.1007/s00262-015-1763-8.

    3. Cremer C., Vierbuchen T., Hein L., Fischer R., Barth S.*, Nachreiner T.* - Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential. J Immunother 38(3): 85-95 (2015), PMID: 25710248, doi: 10.1097/CJI.0000000000000053.

    4. Eersels K., van Grinsven B., Korshid M., Somers V., Püttmann C., Stein C., Barth S., Dilien H., Bos G., Germeraad W., Cleij T., Thoelen R., De Ceuninck W., Wagner P. - Heat-transfer method based cell culture quality assay through cell detection by surface imprinted polymers. Langmuir 31(6): 2043-2050 (2015), PMID: 25654744, doi: 10.1021/la5046173.

    5. Eersels K., van Grinsven B., Vandenryt T., Monroy K.L.J., Peeters M., Somers V., Püttmann C., Stein C., Barth S., Bos G., Germeraad W., Dilien H., Cleij T.J., Thoelen R., De Ceuninck W., Wagner P. - Improving the sensitivity of the heat-transfer method (HTM) for cancer cell detection with optimized sensor chips. Phys Status Solidi A 212(6): 1320-6 (2015), doi: 10.1002/pssa.201431709.

    6. Fitting J., Blume T., ten Haaf A., Blau W., Gattenlöhner S., Tur M.K., Barth S. - Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. mAbs 7(2): 390-402 (2015), PMID: 25760770, doi: 10.1080/19420862.2015.1007818.

    7. Gremse F., Theek B., Kunjachan S., Lederle W., Pardo A., Barth S., Lammers T., Naumann U., Kiessling F. - Absorption reconstruction improves biodistribution assessment of fluorescent nanoprobes using hybrid fluorescence-mediated tomography. Theranostics 4(10): 960-971 (2014), PMID: 25157277, doi: 10.7150/thno.9293.

    8. Hristodorov D., Mladenov R., Schiffer S., Aslanian E., Huhn M., von Felbert V., Fischer R., Barth S.*, Thepen T.* - Targeting CD64 mediates elimination of M1 but not M2 macrophages in chronic cutaneous inflammation. mAbs 7(5): 853-62 (2015), PMID: 26218624, doi: 10.1080/19420862.2015.1066950.

    9. Kapelski S., Boes A., Spiegel H., de Almeida M., Klockenbring T., Reimann A., Fischer R., Barth S., Fendel R. - Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody. Malaria J 14(1): 50 (2015), PMID: 25651860, doi: 10.1186/s12936-015-0577-7.

    10. Kapelski S., de Almeida M., Fischer R., Barth S.*, Fendel R.* - Antimalarial activity of granzyme B and its targeted delivery ba a granzyme B-scFv fusion protein. Antimicrob Agents Chemother 59(1): 669-672 (2015), PMID: 25313223, doi: 10.1128/AAC.04190-14.

    11. Maskus D.J., Bethke S., Seidel M., Kapelski S., Addai-Mensah O., Boes A., Edgü G., Spiegel H., Reimann A., Fischer R., Barth S., Klockenbring T., Fendel R. – Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10. Malaria J 14(1): 276 (2015), PMID: 26174014., doi: 10.1186/s12936-015-0797-x.

    12. Mladenov R., Hristodorov D., Cremer C., Hein L., Kreutzer F., Stroisch T., Niesen J., Brehm H., Blume T., Brümmendorf T., Jost E., Thepen T., Fischer R., Stockmeyer B., Barth S.*, Stein C. - The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. Int J Cancer 137(11): 2729-38 (2015), doi: 10.1002/ijc.29628.

    13. Niesen J., Stein C., Brehm H., Hehmann-Titt G., Fendel R., Melmer G., Fischer R., Barth S. - Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. J Cancer Res Clin Oncol 141(12): 2079-95 (2015), PMID: 25899161, doi: 10.1007/s00432-015-1975-5.

    14. ten Haaf A., Pscherer S., Fries K., Barth S., Gattenlöhner S., Tur M.K. - On slide selection of patient SCLC tissue (FFPE) for generation of novel diagnostic and therapeutic antibodies by phage display. Immunol Let 166(2): 65-78 (2015), PMID: 26045318, doi: 10.1016/j.imlet.2015.05.013.

  • 2014

    1. Berges N., Hehmann-Titt G., Hristodorov D., Melmer G., Thepen T., Barth S. - Human cytolytic fusion proteins: modified versions of human Granzyme B and Angiogenin have the potential to replace bacterial toxins in targeted therapies against CD64+ diseases. Antibodies 3(1): 92-115 (2014)

    2. Bers K., Eersels K., van Grinsven B., Daemen M., Bogie J.F., Hendriks J.J., Bouwmans E.E., Püttmann C., Stein C., Barth S., Bos G.M., Germeraad W.T., De Ceuninck W., Wagner P. - Heat-transfer resistance measurement method (HTM)-based cell detection at trace levels using a progressive enrichment approach with highly selectice cell binding surface imprints. Langmuir 30(12): 3631-3639 (2014), PMID: 24606112, doi: 10.1021/la5001232.

    3. Bialon M., Schellenberg L., Herzog N., Kraus S., Jörißen H., Fischer R., Stein C., Nähring J., Barth S.*, Püttmann C.* - Cloning murine antibody V-genes with non-degenerate primers and conversion to a recombinant antibody format. Monoclon Antib Immunodiagn Immunother 33(6): 369-377 (2014), PMID: 25545205, doi: 10.1089/mab.2014.0044.

    4. Blohm L., Püttmann C., Holz S., Piechotta G., Albers J., Dammers C., Kleines M., Krüttgen A., Melmer G., Nähring J., Barth S.*, Nebling E.* - Rapid detection of human anti-HCV immunoglobulins on electrical biochips. Antibody Technology Journal 4: 23-32 (2014),  DOI: 10.2147/ANTI.S54763

    5. Brehm H., Niesen J., Mladenov R., Stein C., Pardo A., Fey G., Helfrich W., Fischer R., Gattenlöhner S., Tur M.K., Barth S. - A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissue. Cancer Lett 352(2): 228-235 (2014), PMID: 25016058, doi: 10.1016/j.canlet.2014.07.006.

    6. Buchenauer A., Bialon M., Segun D., Püttmann C., Stein C., Barth S., Schnakenberg U. - Plasmonic flow-through biosensor using a polymeric substrate. J Micromech Microeng 24(3): 034001 (2014), doi: 10.1088/0960-1317/24/3/034001

    7. Höfig I., Barth S., Salomon M., Jagusch V., Atkinson M.J., Anastasov N., Thirion C. - Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein. Biomaterials 35(13): 4204-4212 (2014), PMID: 24529898, doi: 10.1016/j.biomaterials.2014.01.051.

    8. Hristodorov D., Amoury M., Mladenov R., Niesen J., Arens K., Berges N., Hein L., Di Fiore S., Pham A.-T., Huhn M., Helfrich W., Fischer R., Thepen T., Barth S. - EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein. Molecular Cancer Therapeutics 13(9): 2194-2202 (2014), PMID: 24980949, doi: 10.1158/1535-7163.MCT-13-0781.

    9. Hristodorov D., Mladenov R., Brehm H., Fischer R., Barth S.*, Thepen T. – Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody - a potential strategy to enhance anti-TNF-alpha therapy. mAbs 6(5): 1283-1289 (2014), PMID: 25517313, doi: 10.4161/mabs.32182.

    10. Hristodorov D., Nordlohne J., Mladenov R., Schiffer S., Huhn M., Fischer R., Thepen T., Barth S. – Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo. Brit J Haematol 164(2): 251-257 (2014), PMID: 24164493, doi: 10.1111/bjh.12626.

    11. Kapelski S., Klockenbring T., Fischer R., Barth S., Fendel R. - Assessment of the neutropilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum. J Leukocyte Biol 96(6): 1131-1142 (2014), PMID: 251118179, doi: 10.1189/jlb.4A0614-283RR.

    12. Niesen J., Brehm H., Stein C., Berges N., Pardo A., Fischer R., ten Haaf A., Gattenlöhner S., Tur M.K., Barth S. - In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomysarcoma cells. J Cancer Res Clin Oncol 141(6): 1049-61 (2014), PMID: 25433506, DOI:10.1007/s00432-014-1884-z.

    13. Schiffer S., Rosinke R., Jost E., Hehmann-Titt G., Huhn M., Melmer G., Barth S.*, Thepen T.* – Targeted ex vivo reduction of CD64-positive monocytes in CMML and AMML using human granzyme B-based cytolytic fusion proteins. Int J Cancer 135(6): 1497-1508 (2014), PMID: 24523193, doi: 10.1002/ijc.28786.

    14. Schirrmann T., Steinwand M., Wezler X., Ten Haaf A., Tur M.K., Barth S. - CD30 as a therapeutic target for lymphoma. BioDrugs 28(2): 181-209 (2014), PMID: 24043362, doi: 10.1007/s40259-013-0068-8

  • 2013

    1. Amoury M., Blume T., Brehm H., Niesen J., Tenhaef N., Barth S., Helfrich W., Fitting J., Nachreiner T., Pardo A. – SNAP-Tag based agents for preclinical in vitro imaging in malignant diseases. Current Pharmaceutical Design 19: 5429-5436 (2013), doi: 10.2174/13816128113199990405

    2. Barth S. – The SNAP-tag technology – a versatile tool with many applications. Current Pharmaceutical Design 19(30): 5404-5405 (2013)

    3. Hehmann-Titt G., Schiffer S., Berges N., Melmer G, Barth S. – Improving the therapeutic potential of human granzyme B for targeted cancer therapy. Antibodies 2(1): 19-49 (2013)

    4. Hristodorov D., Mladenov R., Pardo A., Pham A.T., Huhn M., Fischer R., Thepen T., Barth S. – Microtubule-associated protein (MAP) tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumor model in vivo. Brit J Cancer 109(6): 1570-1578 (2013), PMID: 23942071, doi: 10.1038/bjc.2013.457.

    5. Hussain A.F., Amoury M., Barth S. – SNAP-Tag technology: a powerfull tool for site-specific conjugation of therapeutic agents. Current Pharmaceutical Design 19: 5437-5442 (2013)

    6. Hussain A.F., Krüger H.R., Kampmeier F., Weissbach T., Licha K., Kratz F., Haag R., Calderon M., Barth S. – Targeted delivery of dendritic polyglycerol-doxorubicin conjugates by scFv-SNAP fusion protein suppresses EGFR+ cancer cell growth. Biomacromolecules 14(8): 2510-2520 (2013), PMID: 23782069, doi: 10.1021/bm400410e.

    7. Hussain A.F., Tur M.K., Barth S. – An aptamer-siRNA chimera silences eukaryotic elongation factor 2 gene and induces apoptosis in n3 integrin expressing cancer cells. Nucleic Acid Therapeutics 23(3): 203-212 (2013), PMID: 23544955, doi: 10.1089/nat.2012.0408.

    8. Kolberg K., Püttmann C., Pardo A., Fitting J., Barth S. – SNAP-Tag technology: a general introduction. Current Pharmaceutical Design 19: 5406-5413 (2013)

    9. Puettmann C., Kolberg K., Hagen S., Schmies S., Fischer R., Naehring J. Barth S. – A monoclonal antibody for the detection of SNAP/CLIP-labeled proteins. Immunol Lett 150(1-2): 69-74 (2013), doi: 10.1016/j.imlet.2012.10.007

    10. Schiffer S., Hansen H., Hehmann-Titt G., Huhn M., Fischer R., Thepen T., Barth S. - Efficacy of an adapted Granzyme B-based anti-CD30 cytolytic fusion protein against Serpin B9-positive, treatment-resistant Hodgkin lymphoma cells. Blood Cancer Journal 3: e106 (2013), PMID: 23524591, doi: 10.1038/bcj.2013.4.

    11. Schiffer S., Hristodorov D., Mladenov R., Aslanian E., Huhn M., Fischer R., Barth S.*, Thepen T.* – Species-dependent functionality of the human cytolytic fusion proteins Granzyme B-H22(scFv) and H22(scFv)-angiogenin in macrophages. Antibodies 2(1): 9-18 (2013), doi: 10.3390/antib2010009

    12. Schiffer S., Letzian S., Jost E., Mladenov R., Hristodorov D., Huhn M., Fischer R., Barth S.*, Thepen T.* – Granzyme M as a novel effector molecule for human cytolytic fusion proteins:. CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells. Cancer Lett 341(2): 178-185 (2013), PMID: 23973499, doi: 10.1016/j.canlet.2013.08.005.

    13. Simon-Keller K., Barth S., Vincent A., Marx A. – Targeting the fetal acetylcholine receptor in rhabdomyosarcoma. Expert Opin Ther Targets 17(2): 127-138 (2013)

  • 2012

    1. Fet N., Fiebeler A., Klinge U., Park J.K., Barth S., Thepen T., Tolba R. – Reduction of activated monocytes after ischemia reperfusion injury diminishes oxidative stress and ameliorates renal damage. Nephrol. Dial. Transplant. 27(8): 3149-3155 (2012)

    2. Frese J., Schuster P., Mertens M.E., Vogg A., Dahlems U., Rongen L., Koch S., Mela P., Melmer G., Barth S., Mottaghy F.M., Schmitz-Rode T., Lammers T., Jockenhövel S., Kiessling F. - Generation and imaging of patient customized implants. Biomed. Tech. 09: 57 (2012)

    3. Hischemöller A., Walter C., Weiler V., Hummel H., Thepen T., Huhn M., Barth S., Hoheisel W., Köhler K., Bremer C., Haase M., Waldeck J. – Labeling of anti-MUC-1 binding single chain Fv fragments to surface upconversion nanoparticles for an initial in vivo molecular imaging proof of principle approach. Int J Mol Sci 13(4): 4153-4167 (2012)

    4. Hristodorov D., Mladenov R., Huhn M., Barth S., Thepen T. – Macrophage-targeted therapy: C64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins 4(9): 676-694 (2012)

    5. Losasso V., Schiffer S., Barth S.*, Carloni P.* – Design of human Granzyme B variants with improved therapeutic potential. Proteins 80(11): 2514-2522 (2012)

    6. Pardo A., Stöcker M., Kampmeier F., Melmer G., Fischer R., Thepen T., Barth S. – In vivo imaging of immunotoxin treatment using Katushka transfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother 61(10): 1617-1626 (2012)

    7. Siepert E.M., Gartz E., Tur M.K., Delbrück H., Barth S.*, Büchs J.* – Short-chain fluorescent tryptophan tags for online detection of functional recombinant proteins. BMC Biotechnology 12: 65 (2012)

  • 2011

    1. Abou-Elkacem L., Gremse F., Barth S., Hoffman R.F., Kiessling F., Lederle W. – Comparison of µCT, MRI, and optical reflectance imaging for assessing the growth of GFP/RFP-expressing tumors. Anticancer Res 31(9): 2907-2913 (2011)

    2. Dreier A., Barth S., Goswami A., Weis J. – Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance? Tumour Biol. 33(1): 85-94 (2011)

    3. Fitting J., Kilian D., Junghanss C., Willenbrock S., Murua Escobar H., Nolte I., Lange S., Barth S.*, Tur M.K.* - Generation of recombinant antibody fragments that target canine dendritic cells by phage display. Veterinary and Comparative Oncology 9(3): 183-195 (2011)

    4. Hussain A., Kampmeier F., von Felbert V., Merk H.F., Tur M.K.*, Barth S.* – SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug. Chem. 22(12): 2487-2495 (2011)

    5. Kraus S., Kleines M., Albers J., Blohm L., Piechotta G., Püttmann C., Barth S., Nähring J., Nebling E. – Quantitative measurement of human anti-HCV core immunoglobulins on an electrical bioship platform. Biosensors Bioelectronics 26(5): 1895-1901 (2011)

    6. Recker T., Haamann D., Schmitt A., Küster A., Klee D., Barth S., Müller-Newen G. – Directed covalent immobilization of fluorescently labeled cytokines. Bioconjug. Chem. 22(6): 1210-1220 (2011)

    7. Tur M.K., Huhn M., Jost E., Thepen T., Brümmendorf H., Barth S. – In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA’ in a human acute myeloid leukemia xenograft tumor model. Int. J. Cancer 129(5): 1277-1282 (2011)

  • 2010

    1. Dembski S., Gellermann C., Probst J., Klockenbring T., Barth S. – Multifunctional nanoparticles for biomedical applications. GIT Laboratory Journal 14(11-12): 9-10 (2010)

    2. Gattenlöhner S., Jörißen H., Huhn M., Vincent A.C., Beeson D., Tzartos S., Mamalaki A., Etschmann B., Müller-Hermelink H.K., Koscielniak E., Barth S.*, Marx A.* - A Human Recombinant Autoantibody-based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth in vitro and in a Murine Transplantation Model. J. Biomed. Biotechnol. 2010: Article ID 187621 (2010)

    3. Kampmeier F., Niesen J., Koers A., Ribbert M., Brecht A., Fischer R., Kießling F., Barth S.*, Thepen T.* – Rapid optical imaging of EGF-receptor expression with a single chain antibody SNAP-tag fusion protein. European Journal of Nuclear Medicine and Molecular Imaging 37(19): 1926-1934 (2010)

    4. Ribbert T., Thepen T., Tur M.K., Fischer R., Huhn M., Barth S. – Recombinant, ETA’-based CD64 immunotoxins: Improved efficacy by increased valency, both in vitro as well as in vivo in a chronic cutaneous inflammation model in hC64-transgenic mice. Br. J. Dermatology 2: 279-286 (2010)

    5. Simon-Keller K., Paschen A., Eichmüller S., Gattenlöhner S., Barth S., Koscielniak E., Leuschner I., Stöber P., Hombach A., Abken H., Marx A. – Adoptive T-cell therapy of rhabdomyosarcoma. Pathologe 31 (S2): 215-220 (2010)

  • 2009

    1. Barth S. – Recombinant immunotoxins – The next generation. Current Pharmaceutical Design 15 (23): 2650-2651 (2009)

    2. Joerissen H., Bektas N., Dahl E., Hartmann A., ten Haaf A., Di Fiore S., Kiefer H., Thess A., Barth S.*, Klockenbring T.* - Production and characterization of monoclonal antibodies against RAI3 and its expression in human breast cancer. BMC Cancer 9: 200 (2009)

    3. Kampmeier F., Ribbert M., Nachreiner T., Demsky S., Beaufils F., Brecht A., Barth S. – Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-methylguanine DNA alkyltransferase. Bioconjug. Chem. 20(5): 1010-1015 (2009)

    4. Ranft K., Thepen T., Fischer R., Barth S.*, Stöcker M.* - Recombinant bispecific single chain antibody fragments induce Fc-gamma receptor mediated elimination of CD30+ lymphoma cells. Cancer Lett. 282(2): 187-194 (2009)

    5. Rosenblum M.G., Barth S. – Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Current Pharmaceutical Design 15 (23): 2676-2692 (2009)

    6. Schmitt K., Bolwien C., Sulz G., Koch W., Dunkhorst W., Lödding H., Schwarz K., Holländer A., Klockenbring T., Barth S., Seidel B., Hofbauer W., Rennebarth T., Renzl A. – Fast detection of air contaminants using immunobiological methods. Proceedings of the SPIE – The International Society for Optical Engineering: 736207-736219 (2009)

    7. Thepen T., Huhn M., Melmer G., Tur M.K., Barth S. – Fcg receptor 1 (CD64), a target beyond cancer therapy. Current Pharmaceutical Design 15 (23): 2712-2718 (2009)

    8. Thumann G., Stöcker M., Maltusch C., Salz A., Barth S., Walter P., Johnen S. – High efficient non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Therapy 17(2): 181-189 (2009)

    9. Tur M.K., Neef I., Jäger G., Teubner A., Stöcker M., Melmer G., Barth S. – Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy. Current Pharmaceutical Design: Current Pharmaceutical Design 15 (23): 2693-2699 (2009)

    10. Tur M.K., Neef I., Jost E., Galm E., Jäger G., Stöcker M., Ribbert M., Osieka R., Barth S. – Targeted restoration of downregulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J. Immunother. 32 (5): 431-441 (2009)

    11. Wüllner U., Neef I., Tur M.K., Barth S. – Targeted delivery of RNA interference based drugs. Strategies for in vivo delivery of RNA interference based drugs. Recent Patents in anti-Cancer Drug Discovery 4(1): 1-8 (2009)

  • 2008

    1. Hetzel C., Bachran C., Fischer R., Fuchs H., Barth S.*, Stöcker M.* – Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin against CD64-positive acute myeloid leukemia cells. J. Immunother. 31(4): 370-376 (2008)

    2. Nachreiner T., Kampmeier F., Thepen T., Fischer R., Barth S.*, Stöcker M.* – Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. J. Neuroimmunology 195(1-2): 28-35 (2008)

    3. Stahnke B., Thepen T., Stöcker M., Rosinke R., Jost E., Fischer R., Tur M.K., Barth S. – Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukaemia of monocyte subtypes. Molecular Cancer Therapeutics 7(9): 2924-2932 (2008)

    4. Stöcker M., Pardo A., Hetzel C., Reutelingsperger C., Fischer R., Barth S. – Eukaryotic expression and secretion of EGFP-labeled annexin A5. Prot. Expr. Purif. 58: 325-331 (2008)

    5. Wüllner U., Neef I., Eller A., Kleines M., Tur M.K., Barth S. – Cell-Specific Induction of Apoptosis by Rationally Designed Bivalent Aptamer-siRNA Transcripts Silencing Eukaryotic Elongation Factor 2. Curr. Cancer Drug Targets 8(7): 554-465 (2008) 

  • 2005

    1. Stöcker M., Klockenbring T., Huhn M., Nachreiner T., Wicklein D., Petersen A., Bauer R., Goerlich R., Fischer R., Barth S. – Antigen-specific targeting and elimination of EBV-transformed B-cells by allergen-toxins. Journal of Allergy and Clinical Immunology 116(4): 910-915 (2005).

  • 2004

    1. Heuser C., Barth S., Diehl V., Abken H., Hombach A. – An anti-CD30-scFv-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma-derived tumor cells. Int. J. Cancer 110(3): 386-394 (2004).

    2. Matthey B., Borchmann P., Schnell R., Tawadros S., Lange H., Tur M.K., Huhn M., Klimka A., Barth S., Engert A., Hansen H.P. – Metalloproteinase inhibition augments anti-tumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int. J. Cancer 111(4): 568-574 (2004).

  • 2003

    1. Tur M.K., Huhn M., Thepen T., Stöcker M., Krohn R., Vogel S., Jost E., Osieka R., van de Winkel J.G., Fischer R., Finnern F., Barth S. - Recombinant CD64-specific single chain Immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res. 63 (23): 8414-8419 (2003).

  • 2002

    1. Hansen H.P., Matthey B., Barth S., Kisseleva T., Mokros T., Davies S.J., Beckett R.P., Foelster-Holst R., Lange H.H., Engert A., Lemke H. - Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int. J. Cancer 98(2): 210-215 (2002)

  • 2001

    1. Huhn M., Sasse S., Tur M.K., Matthey B., Schinköthe T., Rybak S., Barth S., Engert A. - Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. 61(24): 8737-8742 (2001)

  • 2000

    1. Barth S., Huhn M., Matthey B., Klimka A., Galinski E.A., Engert A. - Compatible solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl. Environm. Microbiol. 66(4): 1572-1579 (2000)

    2. Barth S., Huhn M., Matthey B., Schnell R., Tawadros S., Schinköthe T., Lorenzen J., Diehl V., Engert A. - Recombinant anti-CD25 immunotoxin RFT5(scFv)-ETA' demonstrates successful elimination of disseminated human Hodgkin´s lymphoma in SCID mice. Int. J. Cancer 86: 718-724 (2000)

    3. Barth S., Huhn M., Matthey B., Tawadros S., Schnell R., Diehl V., Engert A. - Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 95 (12): 3909-3914 (2000)

    4. Klimka A., Matthey B., Roovers R., Barth S., Bot F., Arends J.W., Engert A., Hoogenboom H.R. - Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. Brit. J. Cancer 83: 252-260 (2000)

    5. Pfitzner T., Engert A., Wittor H., Schinköthe T., Winkler U., Schulz H., Diehl V., Barth S. - A real-time PCR assay for the quantification of residual malignant cells in monoclonal B-cell lymphomas. Leukemia 14: 754-766 (2000)

    6. Schnell R., Vitetta E., Schindler J., Borchmann P., Barth S., Ghetie V., Hell K., Drillich S., Diehl V., Engert A. - Treatment of refractory Hodgkin´s lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leuk. 14: 129-135 (2000)

  • 1999

    1. Klimka A., Barth S., Matthey B., Roovers R.C., Lemke H., Hansen H., Arends J.W., Diehl V., Hoogenboom H.R., Engert A. - An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Brit. J. Cancer 80(8): 1214-1222 (1999)

  • 1997

    1. Engert A., Diehl V., Schnell R., Radzuhn A., Hatwig M.T., Drillich S., Schön G., Bohlen H., Tesch H., Hansmann M.L., Barth S., Schindler J., Ghetie V., Uhr J., Vitetta E.S. - A phase-I study of an anti-CD25 ricin A chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin´s lymphoma. Blood 89: 403-410 (1997)

  • 1996

    1. Schnell R., Katouzi A.A., Linnartz C., Schoen G., Drillich S., Hansmann M.L., Schiefer D., Barth S., Zangemeister-Wittke U., Stahel R.A., Diehl V., Engert A. - Potent antitumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt´s lymphoma model in SCID mice. Int. J. Cancer 66: 526-531 (1996)